iRhythm Technologies Inc
Aperta
SettoreSettore sanitario
113.79 0.76
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
112.75
Massimo
114.13
Entrata | -20M -14M |
|---|---|
Vendite | -9.5M 199M |
EPS | -0.35 |
Margine di Profitto | -6.988 |
Dipendenti | 2,400 |
EBITDA | -21M -5.3M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +56.06% upside |
Utili prossimi | 30 lug 2026 |
|---|
Capitalizzazione di Mercato | -614M 3.5B |
|---|---|
Apertura precedente | 113.03 |
Chiusura precedente | 113.79 |
Notizie sul Sentiment di mercato
By Acuity
86%
14%
321 / 342 Classifica in Healthcare
iRhythm Technologies Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.